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GSH EXTRUSION IN APOPTOSIS
Damaged cells opting for apoptosis
actively extrude glutathione in the reduced
form as an apical event in the apoptotic
signaling (Ghibelli et al., 1995; Van den
Dobbelsteen et al., 1996). Apoptotic GSH
efflux is very rapid and, as a consequence,
cells undergo redox imbalance and become
susceptible to oxidative stress due to
loss of ROS scavenging power (D’Alessio
et al., 2003); moreover, the sudden redox
disequilibrium causes the formation of
inter-protein disulfides among reactive
exposed cysteines, altering cell functions
and signaling in a pro-apoptotic fashion
(Circu and Aw, 2012).
GSH EFFLUX IN THE LIFE AND DEATH OF A
CELL
Glutathione is synthesized in the cell
cytosol, and acts essentially as an intra-
cellular antioxidant. However, viable cells
(mainly hepatocytes and macrophages)
extrude GSH as part of their physiological
functions; this provides antioxidant pro-
tection to the extracellular environment
(Bachhawat et al., 2013). The passage of
GSH through plasma membrane is reg-
ulated by a switch in the open/closed
configuration of the transporters, and
occurs according to gradient, being in
fact uni-directional (i.e., export rather
than import) because intracellular lev-
els are much higher than those of body
fluids. GSH transporters were originally
functionally identified as belonging to the
sinusoidal or canalicular type according
to their position in the hepatic anatomy,
and to their responsiveness to specific
inhibitors (Yi et al., 1995). However,
their molecular nature is still elusive
(Bachhawat et al., 2013). Based on several
experimental evidences, the prevalent
current opinion is that GSH transporters
coincide with the multi-drug resistance
associated proteins (MRP) (Ballatori et al.,
2009; Franco and Cidlowski, 2012), which
constitute the complexes responsible
for cell detoxification from xenobiotics
through the export of glutathione-S
conjugates produced by glutathione-S-
transferase (Pompella et al., 2003). The
regulation of the activity of GSH trans-
porters is still unexplored, possibly being
controlled by the differential concentra-
tion of GSH in the vicinity of the carriers
in the internal vs. external face of the cell
membrane, thereby relying in the zonal
control of GSH levels by intracellular
trafficking.
A different scenario applies to the
export of the oxidized glutathione dimers
(GSSG) formed during oxidative stress
(and not reduced back to GSH by glu-
tathione reductase). Even though GSSG
was shown to be target of MRP (Ballatori
et al., 2009), in conditions of oxidative
stress GSSG exits from cells passively cross-
ing the plasma membrane. This mecha-
nism helps avoiding a dangerous drop in
the GSH/GSSG ratio due to the accumu-
lation of GSSG, and the consequent redox
imbalance.
Glutathione loss in apoptosis has been
subject of intense investigation. Most
apoptotic cells become devoid of glu-
tathione even before rupture of the
plasma membrane (Ghibelli et al., 1995),
which indicates an active phenomenon
of extrusion. In instances of apopto-
sis induced by oxidative insults, a pas-
sive efflux of GSSG was observed (Esteve
et al., 1999); in this case, GSH loss
is a consequence of oxidative stress. In
instances of apoptosis induced by non-
oxidative insults, glutathione is extruded
outside cells in the reduced form imme-
diately prior to the execution of apoptosis
(Ghibelli et al., 1995; Van den Dobbelsteen
et al., 1996), followed by ROS produc-
tion as a consequence (D’Alessio et al.,
2003); in this case, GSH loss is the cause,
rather than the consequence of oxidative
stress.
Apoptotic GSH extrusion is prevented
by inhibitors of the sinusoidal GSH trans-
porters (Ghibelli et al., 1998), indicat-
ing that apoptotic GSH efflux follows
the same route as physiological GSH
export. However, while healthy cells shed
only a limited fraction of their GSH, in
apoptosis the efflux leads to complete
GSH depletion, suggesting that the trans-
porters remain stably in an open config-
uration. The events that cause this phe-
nomenon are still unknown; we have
preliminary evidence that the activation
of the apoptotic protease caspase-2, but
not the other caspases, is required for
apoptotic GSH efflux, suggesting that a
proteolytic event (the digestion of an
inhibitor of the transporters?), might
cause an irreversible opening of the
GSH transporters (De Nicola et al., in
preparation).
ROLE OF APOPTOTIC GSH EXTRUSION
GSH extrusion is a necessary step of the
apoptotic signal transduction (Coppola
and Ghibelli, 2000), occurring as an apical
and causative event, as shown by stud-
ies demonstrating that inhibitors of GSH
efflux also inhibit apoptosis (Ghibelli et al.,
1998). The block of the apoptotic signal-
ing occurs as a very early step, because
even apical events such as Bax transloca-
tion are prevented. Antioxidants do not
hamper apoptotic GSH efflux, but pro-
tect GSH-depleted cells from apoptosis
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(Liuzzi et al., 2003), indicating that the
sudden GSH drop activates a redox-
sensitive target among the apical pro-
apoptotic proteins. A likely target is Bax, a
pro-apoptotic member of the Bcl-2 family
that in apoptosis moves to mitochondria,
where it is responsible for the release of
cytochrome c and the consequent caspase
activation and cell demise (Ghibelli and
Diederich, 2010). Bax has two exposed cys-
teines (Suzuki et al., 2000) able to form
inter-protein disulfide bridges upon oxida-
tion (D’Alessio et al., 2005), and therefore
it can be at the same time a sensor of oxida-
tion and an effector of apoptosis. Indeed,
Bax was experimentally shown to assemble
in an oxidative dimer configuration, puta-
tively forming a disulfide between cysteine
62 and cysteine 126, thereby acquiring
the ability to translocate to mitochon-
dria (D’Alessio et al., 2005) and promote
cytochrome c release (Ghibelli et al., 1999).
Damage-induced apoptosis was shown
to follow either redox-sensitive or -
insensitive routes, characterized by GSH
depletion or retention, respectively,
through alternative biochemical routes
that can be morphologically identified (De
Nicola et al., 2006). Leukemic cells display
multiple nuclear apoptotic morphologies;
in particular, two types of nuclear vesic-
ulation (budding and cleavage) are the
result of two independent morphological
routes, since they never interconvert and
are differently modulated by damage vs.
physiological apoptogenic agents (Dini
et al., 1996). In situ analyses showed that
intracellular GSH is completely extruded
in cells undergoing apoptosis by cleavage,
whereas it is fully maintained in apop-
totic budding cells (De Nicola et al., 2006).
Accordingly, in situ measurement of ROS
levels showed that only cells in cleavage
develop oxidative stress (Celardo et al.,
2011). GSH depletion, and the conse-
quent oxidation, is not only concomitant
to, but is the determinant of the cleavage
route, since inhibition of the sinusoidal
GSH transporters completely prevents the
appearance of the apoptotic cells display-
ing the budding morphology (De Nicola
et al., 2006).
PRO-SURVIVAL PATHWAYS INDUCED
BY GSH DEPLETION
GSH, as a co-factor of the glutathione-
S-transferase set of enzymes, plays a
major role in the detoxification of cells
from exogenous molecules, including
pharmaceutical drugs. The depletion of
GSH, achieved in clinics with the spe-
cific GSH synthesis inhibitor buthionine
sulphoxymine (BSO), is an important
strategy to improve drug efficacy in
anticancer therapies, since many aggres-
sive tumor cells are very efficient in
drug extrusion (multi-drug resistant,
MDR), thereby nullifying the effects
of chemotherapies. In these cases BSO
acts a chemosensitizer, since GSH deple-
tion allows bypassing the MDR obstacle,
achieving efficacious levels of antitumor
drug within MDR cells (Fojo and Bates,
2003).
BSO is a specific inhibitor of glu-
tathione synthase, thereby in BSO-treated
cells the GSH pool is consumed but not
replaced, and its level declines according
to the consumption rate, with a kinetics
that depends on the oxidative status of the
cells. In any case, the depletion is much
slower compared with what occurs dur-
ing apoptosis (hours vs. minutes). This
slow rate gives time to the BSO-treated
cells to adapt to the progressively oxidizing
environment, setting up stress response
pathways aimed at increasing cell survival
(Rahman et al., 2005; Ishii and Mann,
2014). Such responses can be very robust,
and in non-MDR tumor cells BSO, rather
than acting as a chemo-sensitizer, para-
doxically potentiates cell survival, thereby
decreasing the pro-apoptotic efficiency of
anti-tumor drugs (D’Alessio et al., 2004).
The survival responses to GSH deple-
tion include the transcriptional activation
of genes encoding for cell protective pro-
teins, via the nuclear factor kappaB (NF-
kappaB) (Filomeni et al., 2005) or the
NF-E2-related factor 2 (Nrf-2) (Lee et al.,
2008) transcriptional activators.
NF-kappaB is a transcription complex
that in response to many insults, includ-
ing oxidative stress, mediates the trans-
activation of key cell protective proteins
(Morgan and Liu, 2011). BSO-mediated
activation of NF-kappaB leads to mul-
tiple cell-protective responses, such as
the trans-activation of heat shock pro-
tein 27, which stops the apoptotic signal
after Bax translocation and cytochrome
c release (Filomeni et al., 2005), and the
main anti-apoptotic protein Bcl-2. Bcl-2
is over-expressed in BSO-treated cells via
transcriptional activation, both in tumor
cells (D’Alessio et al., 2004) and primary
lymphocytes (Cristofanon et al., 2006) and
monocytes (Cristofanon et al., 2008). The
increased Bcl-2 synthesis compensates for,
and overcome, the faster catabolism of
the Bcl-2 protein occurring in cells with
low GSH levels (Meredith et al., 1998;
D’Alessio et al., 2004), increasing the intra-
cellular Bcl-2 levels up to three-four folds
(D’Alessio et al., 2004). This is achieved
through the activation of the so-called
non-canonical NF-kappaB pathway by a
two-step process. First, as a fast response
to GSH depletion, a ternary disulfide
complex forms between two subunits of
the NF-kappaB component p50 and its
tutoring protein Bcl-3 (Cristofanon et al.,
2009). Second, the complex is then acti-
vated via a mechanism dependent on the
mitogen-activated protein p38, a kinase
that requires high ROS levels (Filomeni
et al., 2003); this occurs as a consequence
of GSH depletion only several hours later
(Limón-Pacheco et al., 2007; Cristofanon
et al., 2009).
Nrf-2 is a transcription factor activated
by redox imbalance via the removal of its
redox-sensitive anchor Keap1 (Kundu and
Surh, 2010), and is devoted to the tran-
scription of genes encoding for glutathione
metabolism and antioxidant enzymes (Li
and Kong, 2009; Ramprasath and Selvam,
2013), thus providing cells with extra
antioxidant defense, and reducing the
apoptotic outcome. It was found that
murine embryonic fibroblasts survive to
BSO treatment due to a strong Nrf-2
response, whereas Nrf-2 deficient cells, or
cells treated with Nrf2 siRNA became sen-
sitive to BSO-induced apoptosis (Lee et al.,
2008).
Therefore, the straightforward use of
BSO as coadjuvant in anticancer thera-
pies should be limited to tumors bearing
MDR cells. Importantly, non-MDR cells
could develop chemo-resistance as a result
of BSO treatment, unless they are tar-
geted with specific RNA interfering agents
to prevent the over-expression of survival
proteins.
CONCLUSIONS
Summarizing, GSH depletion may pro-
mote either pro-apoptotic or pro-survival
pathways depending on the kinetic of
depletion; swift GSH extrusion activates
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FIGURE 1 | Slow vs. fast GSH depletion produce opposite effects on cell survival. Top: BSO
induce slow GSH depletion (hours); the disulfides formed after reaching a threshold level of redox
imbalance possess a cell-survival activity (e.g., the p50 subunit of NF-kappaB). Bottom: the very
rapid GSH extrusion occurring in apoptosis promote the formation of pro-apoptotic disulfides (e.g.,
Bax). The arrows indicate a hypothetical threshold level of GSH depletion after which sulfhydryls
(SH, HS) are oxidized to disulfides (S-S) in each condition.
pro-apoptotic pathways, whereas slower
GSH depletion activates pro-survival
pathways (Figure 1). Intriguingly, both
types of response require increased ROS
levels and formation of inter-protein disul-
fides to be activated. The reactivity of
cysteines depends on the surrounding
aminoacids determining protein confor-
mation, and each inter-protein cystine
forms at fixed levels of oxidation of the
cell microenvironment. It is conceivable
that the reactive cysteines of the proteins
involved in the opposite responses (e.g.,
the cell-protective NF-kappaB component
p50 vs. the pro-apoptotic Bax) may be
differently modulated according to the
swiftness of the redox imbalance, pos-
sibly differently relying in the tutoring
effect of thiol-modifying enzymes such as
thioredoxin or protein disulfide isomerase.
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